【ChiCTR2500110461】Effect of Topical NSAIDs (Diclofenac 0.1%, Nepafenac 0.1%, Nepafenac 0.3%) on Pain Management During Intravitreal Injections: A Prospective, Non-Randomized, Case-Control Trial
ChiCTR2500110461
尚未开始
/
/
/
2025-10-14
/
/
Pain associated with Intravitreal Injections
Effect of Topical NSAIDs (Diclofenac 0.1%, Nepafenac 0.1%, Nepafenac 0.3%) on Pain Management During Intravitreal Injections: A Prospective, Non-Randomized, Case-Control Trial
Effect of Topical NSAIDs on Pain Management During Intravitreal Injections
44000
Primary objective of the study is to measure the effect of the addition of pre-operative topical NSAID on perceived pain during intravitreal injection procedures
非随机对照试验
其它
None
/
Self-funded
/
100
/
2025-10-17
2026-02-20
/
1. Age 18 years or older; 2. Scheduled to receive a monocular intravitreal injection of an anti-VEGF agent; 3. Able to understand, consent, and use the Visual Analog Scale for pain reporting.；
请登录查看1. Known hypersensitivity or allergy to proparacaine, diclofenac, nepafenac, or any other NSAID; 2. Presence of active or severe ocular surface disease (e.g., keratitis, severe dry eye); 3. History of ocular surgery within the past 3 months; 4. Concurrent use of any systemic or topical NSAIDs for any other medical reason; 5. A diagnosed anxiety disorder, severe needle phobia, or inability to comprehend the study protocol.；
请登录查看Fauji Foundation Hospital Rawalpindi, Pakistan
44000
Fauji Foundation Hospital Rawalpindi, Pakistan的其他临床试验
Fauji Foundation Hospital Rawalpindi, Pakistan / Foundation University Medical College Islamabad, Pakistan的其他临床试验
最新临床资讯
-
Nature子刊| 恒瑞HER2 ADC：81.5%患者肿瘤缓解，为何病理“清零”仅3.1%？
医药速览2026-08-31
-
首个！安进降脂药临床III期结果积极
医药速览2026-08-31
-
欧康维视2026-08-31
-
摩熵医药2026-08-31
-
摩熵医药2026-08-31
-
氨基观察2026-08-31
-
瞭望财经2026-08-31
-
药时代2026-08-31
-
Cytiva学堂2026-08-31
-
癌度2026-08-31
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 20 8
-
摩熵咨询 34 38
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 35 47
-
摩熵咨询 28 48
-
摩熵咨询 34 28
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29